Preliminary data from a phase 1b extension study (NCT05292911) involving 64 individuals with MRI-PDFF 10% and BMI 28 kg/m 2 demonstrated that 50%, 44%, and 60% of participants presenting baseline alanine aminotransferase (ALT) 30 IU/L reached combined MRI-PDFF reduction 30% and ALT reduction 17 IU/L at pemvidutide doses of 1.2, 1.8, and 2.4 mg, respectively, vs
They added BPC-157 to Category 2 of substances presenting significant safety risks, noting concerns about immune reactions, peptide impurities, and lack of safety data for any human use
Unfortunately, many individuals with diabetes experience impaired glutathione production
Do not use if pregnant
By reducing this stress, glutathione may help preserve the function of these cells, potentially slowing the onset of gray hair for some individuals
***14-DAY MONEY-BACK GUARANTEE